Comment: Incidence and Risk Factors for Development of Thrombocytopenia in Patients Treated With Linezolid for 7 Days or Greater

Abstract

Get full access to this article

View all access options for this article.

References

Rabon

Fisher

MacVane

. Incidence and risk factors for development of thrombocytopenia in patients treated with linezolid for 7 days or greater. Ann Pharmacother. 2018;52:1162-1164. doi:10.1177/1060028018783498

Hirano

Sakamoto

Tachibana

Ohnishi

Retrospective analysis of the risk factors for linezolid-induced thrombocytopenia in adult Japanese patients. Int J Clin Pharm. 2014;36:795-799. doi:10.1007/s11096-014-9961-6

Ichie

Suzuki

Yasui

et al . The association between risk factors and time of onset for thrombocytopenia in Japanese patients receiving linezolid therapy: a retrospective analysis. J Clin Pharm Ther. 2015;40:279-284. doi:10.1111/jcpt.12260

Takahashi

Takesue

Nakajima

et al . Risk factors associated with the development of thrombocytopenia in patients who received linezolid therapy. J Infect Chemother. 2011;17:382-387. doi:10.1007/s10156-010-0182-1

Hanai

Matsuo

Ogawa

et al . A retrospective study of the risk factors for linezolid-induced thrombocytopenia and anemia. J Infect Chemother. 2016;22:536-542. doi:10.1016/j.jiac.2016.05.003